Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc
about
P2Y12-ADP receptor antagonists: Days of future and pastCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsThe pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistanceApplications of propensity score methods in observational comparative effectiveness and safety research: where have we come and where should we go?Plant extracts inhibit ADP-induced platelet activation in humans: their potential therapeutic role as ADP antagonistsState-of-the-Art: Hypo-responsiveness to oral antiplatelet therapy in patients with type 2 diabetes mellitus.Selecting the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention.Acute coronary syndromes: diagnosis and management, part IClopidogrel: the data, the experience, and the controversies.Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry.Antiplatelet and anticoagulant drugs in interventional radiology.Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaPharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.Abciximab in the management of acute myocardial infarction with ST-segment elevation: evidence-based treatment, current clinical use, and future perspectivesImplementing genotype-guided antithrombotic therapy.Serotonin antagonism improves platelet inhibition in clopidogrel low-responders after coronary stent placement: an in vitro pilot study.Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents.Clinical importance of aspirin and clopidogrel resistanceGenetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysisAn algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial.The impact of smoking on clinical efficacy and pharmacodynamic effects of clopidogrel: a systematic review and meta-analysis.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Clinical evidence of interaction between clopidogrel and proton pump inhibitorsOral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspectiveSignificance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease.Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.Variability in response to clopidogrel: how important are pharmacogenetics and drug interactions?Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.Critical appraisal of ticagrelor in the management of acute coronary syndromeThe interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapyHigh Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and ClopidogrelImpact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation.Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes.Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review.Novel antiplatelet agent use for acute coronary syndrome in the emergency department: a reviewComparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
P2860
Q26745619-32FB74FE-209E-4E75-9E1D-FA4CB97A9571Q26771106-F8C8200E-080E-4366-9B46-BD2ED7A04E6AQ26801867-08DFCDBC-CC56-439E-ABF7-1AC80D407804Q26824850-17760B46-52FA-42A5-BA7A-A94A63F3B6D5Q26849372-22068FA7-4B78-47CE-83BD-F23704348054Q26861282-4090B760-51D6-47BB-BE8D-B11ECCC05DA5Q30373414-B924A242-EC74-46D8-BAD8-11748582ECC8Q30438893-C3BFEDF9-D5B5-402A-9DED-E9274F7F97B3Q30490718-34E70113-C8AC-4787-989E-69D73CD90682Q30573045-890BAE89-2E00-4694-BE5A-1E9B467AD4A0Q30800602-90F25364-E8E6-4E2F-A8C7-DC9B86368C2AQ33395898-4F263E5A-883B-4361-8A77-40BF85FE01EDQ33424820-EF3DDF63-45C3-434C-BD02-FE581ED26771Q33685876-BD931D53-28EB-48BB-BF26-00BB83FC3232Q33952693-9F92FF4F-222B-4523-9BAD-0B36D8431D3CQ33990428-4415C62C-76AB-4CD7-A49B-E826434828C8Q34182816-8CD6EF48-2980-4AE9-8A10-5D90CDAA3C87Q34382431-7A25EB42-E951-49DD-95A2-6A19EF0BE1EFQ34390050-AF5703AD-21FB-404C-B74B-73FA946A03BFQ34564576-A0E2FEE6-B27C-4722-8EEB-C9DDC09F2ACBQ34577974-67C20001-21AA-49E2-B479-542CC520A570Q34751965-F86EB4AE-3D01-4E49-9D6A-2944EA1DF6DBQ34763870-704EC1F3-FCCB-4772-944F-8F838230D256Q34771381-6FFC8056-E57D-4FBC-BDF4-322D599BADF2Q35033722-65EB6110-9207-4CC6-B1A6-D6CE2E559033Q35141772-E2F2A3EA-A8DF-485B-BF90-645EF50A387AQ35174193-ED9AB5E8-826B-45DB-AA81-265DDA4DE0E8Q35176063-AE610B52-BF78-41CD-8916-78CE33CA4C85Q35204942-258ECB4F-97DC-4AD1-986A-4F950C6CBF17Q35373698-E3A0EDD4-8ACA-42E5-9695-17100326A5F5Q35569714-BA7D3124-48E3-43AA-AEFD-262392B2137EQ35660767-8570AF81-FEB6-421C-ABD3-45E5BA0908B6Q35683944-B11ADD61-F2C9-4F77-A704-4A4D27385F8AQ35755253-EB55D12B-D353-41A5-8876-C83A848C5F39Q35758891-1C4DAF4C-8EF4-4990-9512-CAC5103B6A5DQ36082585-CA5D551C-FF38-4E11-88DE-2B4EC7FC27FDQ36160606-7D0ABA71-CB57-4D43-B546-22914C619687Q36302146-3BC98FCA-BFEA-45B2-9DDD-5A3571ECFAAFQ36676694-893C5344-8C35-4F0D-82D2-CD3F7EF3E619Q36688145-44DCBBAA-4B5F-4792-A875-22D054B6E6F9
P2860
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@en
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@nl
type
label
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@en
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@nl
prefLabel
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@en
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@nl
P2093
P50
P921
P1433
P1476
Prasugrel compared with high l ...... gregation-Thrombolysis in Myoc
@en
P2093
Alan D Michelson
Andrew L Frelinger
Carolyn H McCabe
Debra L Miller
Dietmar Trenk
Dominick J Angiolillo
Franz-Josef Neumann
Hanoch Hod
Joseph A Jakubowski
Michelle O'Donoghue
P304
P356
10.1161/CIRCULATIONAHA.107.740324
P407
P577
2007-12-03T00:00:00Z